Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Archimedes™ System for Transparenchymal Nodule Access

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 21-75 years at screening~2. Highly suspicious SPN, defined as distinct nodule with a diameter of ≥8mm in its largest dimension~3. No known endobronchial tumor~4. Tumor located anywhere in parenchymal tissue \>1 cm from pleura and accessible bronchoscopically through a POE.~5. Willing to participate in all aspects of study protocol for duration of study~6. Able to understand study requirements~7. Signs study-related informed consent document~Exclusion Criteria:~1. Any contraindication to bronchoscopy, for example:~   * Untreatable life-threatening arrhythmias~  * Inability to adequately oxygenate the patient during the procedure~  * Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated)~  * Recent myocardial infarction~  * Previously diagnosed high-grade tracheal obstruction~  * Uncorrectable coagulopathy~2. Known coagulopathy~3. Platelet dysfunction or platelet count \< 100 x 103 cells/mm3~4. History of major bleeding with bronchoscopy~5. Suspected pulmonary hypertension: additional testing required, such as echocardiogram~6. Moderate-to-severe pulmonary fibrosis~7. Severe emphysema or COPD: additional testing and PI consent is required~8. Bullae \>5 cm located in vicinity of target SPN~9. Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic biopsy or ATV tunneling, for example:~   * ASA class \> 3~  * \> stage 3 heart failure~  * severe cachexia~  * severe respiratory insufficiency or hypoxia~10. Ongoing systemic infection~11. Contraindication to general anesthesia~12. Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) prior to procedure~13. Participation in any other study in last 30 days~14. Prior thoracic surgery on the same side of the lung as the SPN.~15. Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study.~16. Life expectancy of less than one year.~17. Scheduled for lung surgery within 72hrs post-scheduled diagnostic bronchoscopy~18. Pregnancy

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Navigation and tissue sampling (Type: EXPERIMENTAL): Guided bronchoscopic navigation and lung tissue sampling using the Archimedes System

Based on this trial design, predict the completion outcome and termination type (if applicable).